Hybridon to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
25 Octubre 2004 - 8:01AM
PR Newswire (US)
Hybridon to Present at Rodman & Renshaw Techvest 6th Annual
Healthcare Conference CAMBRIDGE, Mass., Oct. 25
/PRNewswire-FirstCall/ -- Hybridon, Inc. (AMEX:HBY) today announced
that company management will present at the Rodman & Renshaw
Techvest 6th Annual Healthcare Conference at the Waldorf Astoria
Hotel in New York City. Sudhir Agrawal, D.Phil, Hybridon's
President, Chief Executive Officer and Chief Scientific Officer,
will provide an overview of the Company and an update on clinical
and business activities. The presentation will begin at 11:10 a.m.
(ET) on Wednesday, October 27, 2004. Hybridon, Inc. is a leader in
the discovery and development of novel therapeutics based on
synthetic DNA. The Company's focus is to develop therapeutics
independently and with partners based on two proprietary technology
platforms. The first platform incorporates synthetic strands of DNA
(immunomodulatory oligonucleotide or IMO(TM) motifs) that act to
modulate responses of the immune system. The second platform uses
synthetic DNA to block the production of disease-causing proteins
at the cellular level (Antisense technology). Licensees of
Hybridon's technology include Isis Pharmaceuticals, Inc.,
MethylGene, Inc., Aegera Therapeutics, Inc., Migenix Inc.,
Epigenesis Pharmaceuticals, Inc., The Immune Response Corporation,
and Alnylam Pharmaceuticals, Inc. The Company is conducting
clinical trials in oncology patients with HYB2055 (IMOxine(TM)), a
2nd-generation IMO, and with GEM(R)231 (a 2nd-generation antisense
oligonucleotide targeted to protein kinase A) in combination with
irinotecan. Additional information about Hybridon is available at
http://www.hybridon.com/. This press release contains
forward-looking statements concerning Hybridon that involve a
number of risks and uncertainties. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the
foregoing, the words, "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will,"
"may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors
that could cause Hybridon's actual results to differ materially
from those indicated by such forward-looking statements, including
risks as to whether the Company will be able to enter into new
collaborations or maintain its existing collaborations and whether
such collaborations will be successful; whether the Company will
commence clinical trials; whether results obtained in preclinical
studies or early clinical trials will be indicative of results
obtained in future preclinical studies or clinical trials, or
warrant further clinical trials and product development; whether
products based on Hybridon's technology will advance through the
clinical trial process and receive approval from the United States
Food and Drug Administration or equivalent foreign regulatory
agencies; whether, if such products receive approval, they will be
successfully distributed and marketed; whether the patents and
patent applications owned or licensed by Hybridon will protect the
Company's technology and prevent others from infringing it; whether
Hybridon's cash resources will be sufficient to fund product and
clinical development; and such other important factors as are set
forth under the caption "Risk Factors" in Hybridon's Quarterly
Report on Form 10-Q filed on August 6, 2004, which important
factors are incorporated herein by reference. Hybridon disclaims
any intention or obligation to update any forward-looking
statements. Contacts: Hybridon, Inc. Euro RSCG Life NRP
617-679-5500 x 5517 212-845-4268 Robert G. Andersen Robert
Stanislaro (media) E-mail: 212-845-4269 Brian Ritchie (investors)
DATASOURCE: Hybridon, Inc. CONTACT: Robert G. Andersen of Hybridon,
Inc., +1-617-679-5500 ext. 5517, ; or Media - Robert Stanislaro,
+1-212-845-4269, Investors - Brian Ritchie, +1-212-845-4268, both
of Euro RSCG Life NRP for Hybridon, Inc. Web site:
http://www.hybridon.com/
Copyright
Hybridon (AMEX:HBY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Hybridon (AMEX:HBY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024